scholarly journals Transition of an acronym from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease

2021 ◽  
Vol 13 (10) ◽  
pp. 1203-1207
Author(s):  
Shahinul Alam ◽  
Shah Mohammad Fahim
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Metabolic Dysfunction ◽  
Nonalcoholic Fatty Liver

scholarly journals From Nonalcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) – New Terminology in Pediatric Patients as a Step in Good Scientific Direction?

2021 ◽  
Author(s):  
Marta Flisiak-Jackiewicz ◽  
Anna Bobrus-Chociej ◽  
Natalia Wasilewska ◽  
Dariusz Lebensztejn
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Liver Steatosis ◽  
Visceral Obesity ◽  
Metabolic Dysfunction ◽  
Nonalcoholic Fatty Liver ◽  
Set Up ◽  
End Stage

Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the world, which predispose to more serious hepatic conditions. It ranges from simple liver steatosis to nonalcoholic steatohepatitis (NASH), which may progress to cirrhosis and even end-stage liver disease. Since obesity became one of the most important health concerns wordwide, a considerable increase in the prevalance of NAFLD and other metabolic implications has been observed, both in adults, and children. Due to the coexistence of visceral obesity, insulin resistance, dyslipidemia, NAFLD is considered to be the hepatic manifestation of metabolic syndrome (MetS). These relationship between NAFLD and MetS led to set up in adults new term combining both of these conditions, called metabolic dysfunction-associated fatty liver disease (MAFLD). Based of these findings, we propose set of criteria, which may be useful to diagnose MAFLD in children and adolescents.

scholarly journals Hígado graso no alcohólico: certezas e incertidumbres de una epidemia silenciosa

2020 ◽  
Vol 50 (3) ◽  
Author(s):  
Esteban González Ballerga ◽  
Andrea Curia ◽  
Kenneth Cusi
Keyword(s):  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Nonalcoholic Steatohepatitis ◽  
Fatty Liver Disease ◽  
Risk Groups ◽  
Diabetic Patients ◽  
Metabolic Dysfunction ◽  
Type 2 Diabetic Patients ◽  
Nonalcoholic Fatty Liver

Nonalcoholic fatty liver disease (NAFLD) is the most frequent chronic liver disease, with an estimated prevalence of 20-30% in the general population and increased to 60-80% in risk groups. It encompasses the spectrum of diseases ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), which can progress to variable degrees of fibrosis, cirrhosis and all its complications. It is associated with cardiovascular, neoplasm and liver mortality, requiring a multidisciplinary approach. A change in the entity name has recently been suggested and a group of experts has proposed calling it Metabolic (dysfunction) Associated Fatty Liver Disease (MAFLD). This name has not yet been accepted and has generated significant controversy. Due to the increase in its prevalence, nonalcoholic fatty liver disease has become a relevant health problem that requires specific actions for its detection, diagnosis, monitoring and treatment. Identifying patients at risk of progressing to more severe forms is essential but not too easy. Patients with nonalcoholic steatohepatitis should be identified; mainly those with fibrosis, the most important characteristic associated with mortality. The main treatment for all stages of the disease consists of lifestyle interventions and aggressive correction of comorbidities. Other therapies, such as treatment with pioglitazone or GLP-1RA, should be selected and used in patients with nonalcoholic steatohepatitis who are at higher risk of progression of liver and cardiovascular disease, like obese and type 2 diabetic patients.

scholarly journals Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan

2021 ◽  
Author(s):  
Masato Yoneda ◽  
Takuma Yamamoto ◽  
Yasushi Honda ◽  
Kento Imajo ◽  
Yuji Ogawa ◽  
...  
Keyword(s):  
Cardiovascular Disease ◽  
Liver Disease ◽  
Fatty Liver ◽  
Nonalcoholic Fatty Liver Disease ◽  
Fatty Liver Disease ◽  
Incidence Rates ◽  
Point Of View ◽  
Metabolic Dysfunction ◽  
Nonalcoholic Fatty Liver ◽  
Claims Database

Abstract Background Nonalcoholic fatty liver disease (NAFLD) and metabolic dysfunction associated fatty liver disease (MAFLD) have important associations with cardiovascular disease (CVD). The main objective of this study was to compare the frequency of incidence rate of CVD in the NAFLD or MAFLD patients utilizing a large claims database. Methods Using the JMDC database from April 2013 to March 2019, we retrospectively analyzed data for 1,542,688 and 2,452,949 people to estimate the relationship between CVD and NAFLD, MAFLD, respectively. Results The incidence rates of CVD were 0.97 (95% CI 0.94–1.01) and 2.82 (95% CI 2.64–3.01) per 1000 person-years in the non-NAFLD and NAFLD groups, respectively, and 1.01 (95% CI 0.98–1.03) and 2.69 (95% CI 2.55–2.83) per 1000 person-years in the non-MAFLD and MAFLD groups, respectively. The overall prevalence of hypertriglyceridemia and diabetes mellitus (DM) was 13.1, and 4.2%, respectively, in the non-NAFLD group and 63.6, and 20.2%, respectively, in the NAFLD group. The overall prevalenceof hypertriglyceridemia and DM was 13.6 and 4.3%, respectively, in the non-MAFLD group and 64.1, and 20.6%, respectively, in the MAFLD group. HRs for CVD increased with hypertriglyceridemia and DM. Conclusions Results indicated that incident rate of CVD increased with NAFLD/MAFLD; the complication rate of DM and hypertriglyceridemia among NAFLD/MAFLD patients is high and may affect the development of CVD.

Sign in / Sign up

Export Citation Format

Share Document